Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pediatric Attention Deficit Hyperactivity Disorder
Conditions
Pediatric Attention Deficit Hyperactivity Disorder
Trial Timeline
Jul 1, 2014 → Mar 1, 2015
NCT ID
NCT02195167About Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily is a phase 1 stage product being developed by Sumitomo Pharma for Pediatric Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02195167. Target conditions include Pediatric Attention Deficit Hyperactivity Disorder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02195167 | Phase 1 | Completed |
Competing Products
20 competing products in Pediatric Attention Deficit Hyperactivity Disorder